← Leaderboards
Mark Anthony Lovell
University Of Kentucky
$4,992,096
Attributed
$5,696,959
Total exposure
16
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2007–24$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,696,959 · 16
By mechanism
R42$2,011,773 · 2
R01$1,891,435 · 2
R21$1,167,587 · 3
R41$612,123 · 5
P41$14,041 · 4
Top collaborators
- Kyle Smoot3 shared
- Adam D Bachstetter1 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Adam D Bachstetter$7,223,838
- Kyle Smoot$493,114
- William R Markesbery$12,693,618
- Michael Paul Murphy$8,590,720
- James W Geddes$9,073,491
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposFutureProteinsBaseS DiseaseLegal PatentNeuronsSpecificitySamplingDiagnosisLinkBrainClinical TrialsTau ProteinsInjuryPathogenesisImmunoassayUniversitiesAffectSportsCerebrospinal FluidEnzymesDiagnosticDisease Progression
Grant awards (26)
Therapeutic Value of BNC-1 in Addressing Tau Pathology in TBI$423,500
R21 · FY2024 · AG
Validation of a Point of Care Diagnostic Test for Sports Related Concussion$328,450
R01 · FY2020 · NS · contact PI
Validation of a Point of Care Diagnostic Test for Sports Related Concussion$328,747
R01 · FY2019 · NS · contact PI
Commercialization of a Novel Therapeutic for Alzheimer's Disease$551,313
R42 · FY2018 · AG · contact PI
Validation of a Point of Care Diagnostic Test for Sports Related Concussion$329,030
R01 · FY2018 · NS · contact PI
Commercialization of a Rapid Blood Test for Traumatic Brain Injury$197,824
R41 · FY2018 · NS · contact PI
Commercialization of a Novel Therapeutic for Alzheimer's Disease$508,624
R42 · FY2017 · AG · contact PI
Validation of a Point of Care Diagnostic for Traumatic Brain Injury$190,785
R21 · FY2017 · NS · contact PI
Validation of a Point of Care Diagnostic for Traumatic Brain Injury$241,990
R21 · FY2016 · NS · contact PI
Target Identification for Novel Small Molecule Therapeutic for Alzheimer's disease$106,301
R41 · FY2016 · AG · contact PI
Development of a Novel Therapeutic for Alzheimer' Disease$99,973
R41 · FY2012 · AG · contact PI
Development of a Plasma Biomarker of Alzheimer's Disease$99,090
R41 · FY2012 · ES · contact PI
Commercialization of a Diagnostic Test for Alzheimer's Disease$516,113
R42 · FY2011 · AG · contact PI
Commercialization of a Diagnostic Test for Alzheimer's Disease$435,723
R42 · FY2010 · AG · contact PI
FMRI AND SPORTS-RELATED CONCUSSION$3,039
P41 · FY2010 · RR · contact PI
Aberrant Protein Complexes in CSF as Biomarkers of Alzheimer's Disease$155,656
R21 · FY2009 · AG · contact PI
FMRI AND SPORTS-RELATED CONCUSSION$3,406
P41 · FY2009 · RR · contact PI
Aberrant Protein Complexes in CSF as Biomarkers of Alzheimer's Disease$155,656
R21 · FY2008 · AG · contact PI
FMRI AND SPORTS-RELATED CONCUSSION$2,576
P41 · FY2008 · RR · contact PI
Development of a Diagnostic Test for Alzheimer's Disease$108,935
R41 · FY2007 · AG · contact PI
FMRI AND SPORTS-RELATED CONCUSSION$5,020
P41 · FY2007 · RR · contact PI
DISRUPTION OF ZINC HOMEOSTASIS IN ALZHEIMER'S DISEASE$181,000
R01 · FY2004 · AG
DISRUPTION OF ZINC HOMEOSTASIS IN ALZHEIMER'S DISEASE$181,000
R01 · FY2003 · AG
DISRUPTION OF ZINC HOMEOSTASIS IN ALZHEIMER'S DISEASE$181,000
R01 · FY2002 · AG
DISRUPTION OF ZINC HOMEOSTASIS IN ALZHEIMER'S DISEASE$181,000
R01 · FY2001 · AG
DISRUPTION OF ZINC HOMEOSTASIS IN ALZHEIMER'S DISEASE$181,208
R01 · FY2000 · AG